4.5 Review

Current understanding of fibrosis in genetic cardiomyopathies

Journal

TRENDS IN CARDIOVASCULAR MEDICINE
Volume 30, Issue 6, Pages 353-361

Publisher

ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tcm.2019.09.003

Keywords

Fibrosis; Remodeling; Heart failure; Cardiomyopathy; Genetics; Imaging

Funding

  1. Netherlands Heart Foundation (CVON DOSIS) [2014-40]
  2. Leducq Foundation (Cure PhosphoLambaN induced cardiomyopathy (Cure-PLaN))
  3. Netherlands Heart Foundation (CVON SHE-PREDICTS-HF (2017-21))
  4. Netherlands Heart Foundation (CVON RED-CVD (2017-11))
  5. Netherlands Heart Foundation (CVON PREDICT2) [2018-30]
  6. Innovational Research Incentives Scheme program of the Netherlands Organization for Scientific Research (NWO VIDI) [917.13.350]
  7. European Research Council (SECRETE-HF) [ERC CoG 818715]

Ask authors/readers for more resources

Myocardial fibrosis is the excessive deposition of extracellular matrix proteins, including collagens, in the heart. In cardiomyopathies, the formation of interstitial fibrosis and/or replacement fibrosis is almost always part of the pathological cardiac remodeling process. Different forms of cardiomyopathies show particular patterns of myocardial fibrosis that can be considered as distinctive hallmarks. Although formation of fibrosis is initially aimed to be a reparative mechanism, in the long term, on-going and excessive myocardial fibrosis may lead to arrhythmias and stiffening of the heart wall and subsequently to diastolic dysfunction. Ultimately, adverse remodeling with progressive myocardial fibrosis can lead to heart failure. Not surprisingly, the presence of fibrosis in cardiomyopathies, even when subtle, has consistently been associated with complications and adverse outcomes. In the last decade, non-invasive in vivo techniques for visualization of myocardial fibrosis have emerged, and have been increasingly used in research and in the clinic. In this review, we will describe the epidemiology, distribution, and role of myocardial fibrosis in genetic cardiomyopathies, including hypertrophic, dilated, arrhythmogenic, and non-compaction cardiomyopathy, and a few specific forms of genetic cardiomyopathies. (C) 2019 The Author(s). Published by Elsevier Inc.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available